Research ArticleCOAGULATION

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding

See allHide authors and affiliations

Science Translational Medicine  04 Jan 2017:
Vol. 9, Issue 371, eaaf5294
DOI: 10.1126/scitranslmed.aaf5294

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

This antiplatelet agent is just right

Antiplatelet agents are common drugs that are used to prevent thrombotic events such as stroke in patients at high risk. Unfortunately, a frequent side effect of these drugs is excessive bleeding because they indiscriminately suppress thrombotic function. To improve on the safety margin of antiplatelet agents, Wong et al. identified a new target for treatment, a platelet receptor called PAR4. The authors developed a small-molecule drug against this target and evaluated its efficacy and safety in animal models. In head-to-head comparisons, the new drug was no less effective than clopidogrel, an antiplatelet agent widely used in the clinic, but it had a much larger therapeutic window.

View Full Text

Stay Connected to Science Translational Medicine